Clinical Trials Browser

OTHER × Carcinoma, Non-Small-Cell Lung × Docetaxel × Clear all

NCT05800587 2026-05-22

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT01350817 2026-05-15

TARSEQ

Phase 2 Completed

156 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT03611738 2026-05-15

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02495896 2026-04-29

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Gallbladder Neoplasms, Pancreatic Neoplasms

NCT00883480 2026-04-28

SLAT

Phase NA Completed

Carcinoma, Non-Small-Cell Lung

NCT02664935 2026-04-28

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Phase 2 Completed

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT06623656 2026-04-21

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

Phase 2 Recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT05616624 2026-04-15

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT07528274 2026-04-14

Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03158129 2026-04-06

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

Phase 2 Completed

101 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT07001618 2026-04-03

IMMUNOLIFE2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06951646 2026-03-09

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT04884282 2026-02-06

COMBI-TED

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06484491 2026-01-30

HyDose

Phase NA Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07330050 2026-01-09

WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06908993 2025-12-17

COMET

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03137771 2025-11-25

Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Phase 2 Active not recruiting

218 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT00284778 2025-07-24

Pharmaco-economic Study of a Second Line Treatment in Advanced Non Small Cell Lung Cancer

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Phase 1/2 Terminated

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06929936 2025-06-08

PROTECT-1

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT01652820 2025-05-23

GECP0008

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT00446225 2025-03-05

EURTAC

Phase 3 Completed

174 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT05599789 2025-02-18

KeyPemls-004

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT00478699 2024-12-12

GECP-SCAT

Phase 3 Completed

500 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung

NCT04158440 2024-07-09

Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT00254384 2024-07-05

Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT05816499 2024-06-17

AK104IIT018

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03095612 2024-06-13

Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)

Phase 1/2 Terminated

41 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT02225405 2024-05-08

Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT03833440 2024-05-03

PIONeeR

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02889666 2024-04-17

CCODG-NSCLC

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT02922777 2024-02-21

Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT00617656 2024-01-30

BREC

Phase 3 Terminated

382 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06182800 2023-12-27

Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03845270 2023-12-19

R2D2

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT03228186 2023-10-23

Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

Phase 2 Terminated

40 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT05777278 2023-10-10

Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT00118131 2023-08-15

Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2 Terminated

49 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00301808 2023-05-06

Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer

Phase 2 Completed

29 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01257139 2023-04-03

ESOGIA

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung

NCT00970684 2022-08-16

Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Phase 2 Completed

13 enrolled 9 charts

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04878107 2022-05-02

SABRE

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT01059188 2022-03-11

Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03798743 2022-03-02

SUCCESS

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT04772287 2021-02-26

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT02577341 2021-02-11

Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT03256721 2021-02-08

Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT02574598 2021-01-06

MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients

Phase 2 Completed

78 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT04619537 2020-11-18

A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04619563 2020-11-18

A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung